Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2015

View Archived Issues

Revive Therapeutics' bucillamine receives orphan drug designation for cystinuria

Novartis reviews highlights of third quarter 2015

Vaxart awarded BARDA contract to support development of influenza tablet vaccine

Arbutus provides update on HBV pipeline

Igenica Biotherapeutics begins strategic oncology research agreement with MedImmune

Intercept reports results from phase II trial of obeticholic acid in Japanese patients with NASH

BioCision and UCSF collaborate on cell therapy for organ transplantation and diabetes

Diabetes experts review potential link between SGLT2 inhibitors and diabetic ketoacidosis

Galapagos' GLPG-1837 well tolerated in phase I trial, phase II planned

First-in-human study conducted with brain imaging agent [18F]GE-180

Allergan in discussions regarding potential business combination transaction with Pfizer

Alizé Pharma reports data from a Phase Ib trial of AZP-531 in type 2 diabetes

Beryl Therapeutics patents phenanthrolines for liver fibrosis

Daiichi Sankyo describes anti-HER3 ADCs

Takeda Pharmaceutical reports LSD1 inhibitors

Mifcare discloses MIF inhibitors

Novel ASNS gene variants identified in asparagine synthetase deficiency

Newron Pharmaceuticals to conduct sarizotan trial in patients with Rett syndrome

Tetrahedron develops organoselenium antitumor agents

ProNAi begins phase II trial of PNT-2258 in patients with Richter's transformation

PDE10A inhibitor PDM-042 shows promise for treating schizophrenia

Bardoxolone methyl shows promise for the treatment of PAH

Shionogi licenses decubitus ulcer candidate SR-0379 from FunPep

Alkermes updates on development strategy for ALKS-8700

Efficacy data from three studies on obeticholic acid

FDA approves Utibron Neohaler and Seebri Neohaler for COPD

FDA grants fast track designation to Insys' sublingual naloxone for opioid overdose

Phase I data for dengue purified inactivated vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...